Skip to main content
. 2010 Feb 18;181(12):1345–1354. doi: 10.1164/rccm.200906-0978OC

TABLE 3.

CORRELATION BETWEEN HIGH-RESOLUTION COMPUTED TOMOGRAPHY SCORE AND CLINICAL VARIABLES AND BIOMARKERS AT STUDY WEEKS 12 AND 36

Clinical Variable or Biomarker n Correlation Coefficient (Week 12) P Value n Correlation Coefficient (Week 36) P Value
PaO2 35 −0.688 <0.001 35 −0.454 0.006
A–aDO2 35 0.698 <0.001 35 0.416 0.013
DlCO, % predicted 33 −0.594 <0.001 34 −0.482 0.004
LDH 34 0.742 <0.001 35 0.645 <0.001
KL-6 32 0.565 <0.001 35 0.718 <0.001
SP-D 32 0.639 <0.001 35 0.530 0.001
SP-A 32 0.610 <0.001 35 0.551 <0.001
CEA 32 0.504 0.003 35 0.619 <0.001
GM-CSF autoantibody 31 0.081 0.663 34 0.251 0.153

Definition of abbreviations: A–aDO2 = alveolar-arterial oxygen difference; CEA = carcinoembryonic antigen; GM-CSF = granulocyte/macrophage–colony stimulating factor; HRCT = high-resolution computed tomography; KL-6 = a mucin-like glycoprotein; LDH = lactate dehydrogenase; SP = surfactant protein.

Correlation was calculated by comparing the total HRCT score for each individual with various clinical measures and serum biomarkers after completion of high-dose (study week 12) and low-dose (study week 36) GM-CSF inhalation therapy using Spearman correlation coefficient.